Literature DB >> 11360304

Selective dissection of levels II-III with intraoperative control of the upper and middle jugular nodes: a therapeutic option for the N0 neck.

X León1, M Quer, C Orús, F J Sancho, S Bagué, J Burgués.   

Abstract

BACKGROUND: Selective neck dissections are accepted elective treatment in N0 patients. We present the results of a dissection of levels II to III and intraoperative pathologic control of a sample of subdigastric and supraomohyoid nodes in a group of patients with laryngeal carcinoma. When intraoperative analysis was positive, dissection of levels IV and V was completed.
METHODS: Between 1991 and 1997, 145 neck dissections with intraoperative control were carried out in 79 patients with laryngeal carcinomas. Postoperative radiotherapy was used in 49 patients.
RESULTS: There were occult metastases in 29 neck dissections (20%). In 22 cases (15%), tumor was found in the nodes sent to intraoperative pathologic study, and dissection of levels IV and V was completed. In 7 additional cases tumor was found in the postoperative study. The sensitivity of the use of frozen sections in the detection of occult metastases was 76%. In no case were positive nodes found at level V. There was no regional relapse in any of the 145 selective neck dissections.
CONCLUSIONS: The lateral selective neck dissection is an effective method in the elective treatment of the neck of N0 laryngeal carcinoma patients. Dissection of level IV can be spared when intraoperative biopsy specimens of a sample of the subdigastric and supraomohyoid nodes are negative. According to our results, at present we do not consider it necessary to dissect level V in selective neck dissections in patients with laryngeal carcinoma. Copyright 2001 John Wiley & Sons, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11360304     DOI: 10.1002/hed.1148

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  7 in total

Review 1.  Management of the clinically negative (N0) neck.

Authors:  Karen T Pitman; Robert Dean
Journal:  Curr Oncol Rep       Date:  2002-01       Impact factor: 5.075

2.  Intraoperative frozen section for detection of occult metastasis in clinically N0 neck does not improve outcome in oral cavity carcinomas.

Authors:  Swagnik Chakrabarti; Hitesh Rajendra Singhavi; Munita Bal; Manish Mair; Akshat Malik; Ankit Mahuvakar; Arjun Singh; Rachit Mathur; Poonam Joshi; Sudhir Nair; Deepa Nair; Pankaj Chaturvedi
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-05-30       Impact factor: 2.503

Review 3.  Superselective neck dissection: rationale, indications, and results.

Authors:  Carlos Suárez; Juan P Rodrigo; K Thomas Robbins; Vinidh Paleri; Carl E Silver; Alessandra Rinaldo; Jesus E Medina; Marc Hamoir; Alvaro Sanabria; Vanni Mondin; Robert P Takes; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-01-16       Impact factor: 2.503

4.  Is level IIb lymph node dissection always necessary in N1b papillary thyroid carcinoma patients?

Authors:  Jandee Lee; Tae-Yon Sung; Kee-Hyun Nam; Woung Youn Chung; Euy-Young Soh; Cheong Soo Park
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

5.  Cervical metastasis on level IV in laryngeal cancer.

Authors:  V J Furtado de Araújo Neto; C R Cernea; R Aparecido Dedivitis; V J Furtado de Araújo Filho; J Fabiano Palazzo; L Garcia Brandão
Journal:  Acta Otorhinolaryngol Ital       Date:  2014-02       Impact factor: 2.124

6.  Incidence and outcome for patients with occult lymph node involvement in T1 and T2 oral squamous cell carcinoma: a prospective study.

Authors:  Thomas Mücke; David A Mitchell; Stefan Wagenpfeil; Lucas M Ritschl; Klaus-Dietrich Wolff; Anastasios Kanatas
Journal:  BMC Cancer       Date:  2014-05-20       Impact factor: 4.430

7.  Levels II and III neck dissection for larynx cancer with N0 neck.

Authors:  Carlos Takahiro Chone; Hugo Fontana Kohler; Rodrigo Magalhães; Marcos Navarro; Albina Altemani; Agricio Nubiato Crespo
Journal:  Braz J Otorhinolaryngol       Date:  2012-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.